CYBB and Thromboembolism: Proving that NOX2 mediates platelet activation in patients carrying MPHVs, our study gives bench evidence to guidelines’ suggestion to add an antiplatelet agent to VKA therapy in patients undergoing thromboembolism despite adequate INR control [7].